日本語フィールド
著者：*Hidehiro Kaneko, Yuichiro Yano, Hyeok-Hee Lee, Hokyou Lee, Akira Okada, Hidetaka Itoh, Kojiro Morita, Akira Fukui, Katsuhito Fujiu, Yuta Suzuki, Satoshi Matsuoka, Sunao Nakamura, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Akira Nishiyama, Koichi Node, Anthony J Viera, Paul Muntner, Suzanne Oparil, Hyeon Chang Kim, Hideo Yasunaga, Issei Komuro題名：Medication Naïve Blood Pressure and Incident Cancers: Analysis of Two Nationwide Population-Based Databases発表情報：Am J Hypertens 巻: 35 号: 8 ページ: 731-739キーワード：blood pressure; cancer; epidemiology; hypertension概要：Background: Results of preceding studies on the relationship between blood pressure (BP) and cancers have been confounded due to individuals taking antihypertensive medications or shared risk factors. We assessed whether medication-na?ve high BP is a risk factor for incident cancers.
Methods: This retrospective observational study included 1,388,331 individuals without a prior history of cancer and not taking antihypertensive medication enrolled in the JMDC Claims Database between 2005 and 2018. The primary outcome was sixteen cancers.
Results: The median [interquartile range] age was 45 [40-52] years and 56.2% were men. Mean systolic and diastolic BP were 117.7±15.8 mmHg and 72.8±11.6 mmHg. Multivariate Cox regression analysis demonstrated that systolic BP per 1-standard deviation (SD) was associated with a higher incidence of thyroid (hazard ratio [HR]:1.09, 95% confidence interval [CI]:1.03-1.16), esophageal (HR:1.15, 95% CI:1.07-1.24), colorectal (HR:1.04, 95% CI:1.01-1.07), liver (HR:1.11, 95% CI:1.03-1.20), and kidney (HR:1.22, 95% CI:1.14-1.31) cancers, but with a lower incidence of stomach cancer (HR:0.94, 95% CI:0.91-0.98). These associations remained significant after adjustment for multiple testing. Diastolic BP was associated with higher incidences of thyroid, esophageal, colorectal, kidney, and corpus uteri cancers, but with a lower incidence of stomach cancer. The associations between systolic BP and incidences of thyroid, esophageal, colorectal, liver, and kidney cancers were confirmed in the Korean National Health Insurance Service database.
Conclusions: Medication-na?ve BP was associated with higher incidences of thyroid, esophageal, colorectal, liver, and kidney cancers. Uncovering the underlying mechanisms for our results may help identify novel therapeutic approach for hypertension and cancer.抄録：英語フィールド
Author：*Hidehiro Kaneko, Yuichiro Yano, Hyeok-Hee Lee, Hokyou Lee, Akira Okada, Hidetaka Itoh, Kojiro Morita, Akira Fukui, Katsuhito Fujiu, Yuta Suzuki, Satoshi Matsuoka, Sunao Nakamura, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Akira Nishiyama, Koichi Node, Anthony J Viera, Paul Muntner, Suzanne Oparil, Hyeon Chang Kim, Hideo Yasunaga, Issei KomuroTitle：Medication Naïve Blood Pressure and Incident Cancers: Analysis of Two Nationwide Population-Based DatabasesAnnouncement information:Am J Hypertens Vol: 35 Issue: 8 Page: 731-739Keyword：blood pressure; cancer; epidemiology; hypertensionAn abstract：Background: Results of preceding studies on the relationship between blood pressure (BP) and cancers have been confounded due to individuals taking antihypertensive medications or shared risk factors. We assessed whether medication-na?ve high BP is a risk factor for incident cancers.
Methods: This retrospective observational study included 1,388,331 individuals without a prior history of cancer and not taking antihypertensive medication enrolled in the JMDC Claims Database between 2005 and 2018. The primary outcome was sixteen cancers.
Results: The median [interquartile range] age was 45 [40-52] years and 56.2% were men. Mean systolic and diastolic BP were 117.7±15.8 mmHg and 72.8±11.6 mmHg. Multivariate Cox regression analysis demonstrated that systolic BP per 1-standard deviation (SD) was associated with a higher incidence of thyroid (hazard ratio [HR]:1.09, 95% confidence interval [CI]:1.03-1.16), esophageal (HR:1.15, 95% CI:1.07-1.24), colorectal (HR:1.04, 95% CI:1.01-1.07), liver (HR:1.11, 95% CI:1.03-1.20), and kidney (HR:1.22, 95% CI:1.14-1.31) cancers, but with a lower incidence of stomach cancer (HR:0.94, 95% CI:0.91-0.98). These associations remained significant after adjustment for multiple testing. Diastolic BP was associated with higher incidences of thyroid, esophageal, colorectal, kidney, and corpus uteri cancers, but with a lower incidence of stomach cancer. The associations between systolic BP and incidences of thyroid, esophageal, colorectal, liver, and kidney cancers were confirmed in the Korean National Health Insurance Service database.
Conclusions: Medication-na?ve BP was associated with higher incidences of thyroid, esophageal, colorectal, liver, and kidney cancers. Uncovering the underlying mechanisms for our results may help identify novel therapeutic approach for hypertension and cancer.